drugset / Trial / NCT07235033
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2)
RandomizedParallel-groupOpen-labelTreatment
Summary
This was Cohort B2 of the Platform study (NCT05750628) to evaluate the efficacy and safety of Cipargamin + KLU156 in participants with uncomplicated Plasmodium falciparum malaria.
Timeline
- Start
- 2024-01-23
- Primary completion
- 2025-03-05
- Completion
- 2025-03-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Artemether | Small molecule | 80 mg | Oral |
| Subject | Ganaplacide | Small molecule | 400 mg | Oral |
| Subject | cipargamin | Small molecule | 75 mg | Oral |
| Comparator | lumefantrine | Small molecule | 480 mg | Oral |